Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients

HIV Clinical Trials

Volumn 11, Issue 2, 2010, Pages 69-79

  Squires, Kathleen ^a   Young, Benjamin ^b   Dejesus, Edwin ^c   Bellos, Nicholas ^d   Murphy, Daniel ^e   Sutherland Phillips, Denise ^f   Zhao, Henry ^f   Patel, Lisa ^f   Ross, Lisa ^f   Wannamaker, Paul ^f   Shaefer, Mark ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Southwest Infectious Disease Associates   (United States)

^e Clinique Medicale l'Actuel   (Canada)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Abacavir; Atazanavir; Induction antiretroviral therapy; Lamivudine; Ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; HLA B7 ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HLA-B ANTIGENS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; OLIGOPEPTIDES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77953592114     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1102-69     Document Type: Article

References (22)

1. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defi c Syndr. 2006;41:194-200.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed February 10, 2009.
4. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300:555-570.
5. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov. 2003;2:624-634.
6. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV-1 RNA after triple-drug therapy. N Engl J Med. 1998;339:1261-1268.
7. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998;352:185-190.
8. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998;339:1269-1276.
9. Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/ lamivudine/zidovudine alone in antiretroviral- naïve HIV-1 -infected patients. J Acquir Immune Defi c Syndr. 2005;39:257-264.
10. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203-211.
11. Cao K, Hollenbach J, Shi X, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62:1009-1030.
12. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121-1122.
13. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to Aabacavir. N Engl J Med 2008;358:568-579.
14. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111-1117.
15. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2008;47:266-285.
16. Sax P, Tierney C, Collier A, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;23:2230-2240.
17. Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008;22:1673-1675.
18. Ortiz R, DeJesus E, Khanlou H, et al. Effi cacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS. 2008;22:1389-1397.
19. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week effi cacy and safety results of the CASTLE study. Lancet. 2008;372:646-655.
20. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J Am Med Assoc. 2001;286:2560-2567.
21. Ha B, Liao Q, Dix L, Pappa K. Firologic response and safety of the abacavir/lamivudine fi xed-dose formulation as part of highly active antiretroviral therapy: analysis of six clinical studies. HIV Clin Trials. 2009;10(2):65-75.
22. Elion R, DeJesus E, Sension M, et al. Once-daily abacavir/ lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48 week pilot study. HIV Clin Trials. 2008:9(3):152-163.